The Role of Anemia as a Risk Factor for Resistant Hypertension in Chronic Kidney Disease

Authors

  • Salwa Salsabila Nasution Universitas Lampung
  • Intanri Kurniati
  • Maya Ganda Ratna
  • M. Ricky Ramadhian

DOI:

https://doi.org/10.53089/medula.v14i10.1354

Keywords:

Anemia, erythropoietin, chronic kidney disease, hypertension

Abstract

Anemia is one of the most common complications in chronic kidney disease (CKD) that significantly affects quality of life and prognosis. Anemia is a condition where there is a decrease in iron-rich hemoglobin levels, which functions to circulate oxygen throughout the body. Chronic kidney disease is a kidney condition characterized by abnormalities in kidney structure or function. Men have a 2 times higher risk of developing CKD than women due to their generally poorer lifestyle habits. The condition of insufficient oxygen perfusion to tissues leads to activation of the renin-angiotensin-aldosterone system (RAAS). The RAAS system ultimately produces aldosterone and antidiuretic hormones that cause sodium retention in the body and lead to increased blood pressure. Additionally, anemia can cause changes in blood vessels, where there is an increase in vascular resistance, especially in CKD patients. Studies have also shown that erythropoietin therapy can increase the prevalence of hypertension. Resistant hypertension is a condition where someone suffering from hypertension fails to achieve target blood pressure of <140/80 mmHg in normal individuals and <130/80 mmHg in CKD patients despite adhering to a combination dose of three types of antihypertensive medications. Someone suffering from resistant hypertension must comply with the drug dosage prescribed by the doctor and also improve their lifestyle. This article aims to understand how anemia serves as a risk factor for resistant hypertension in CKD patients. Furthermore, the diagnosis and treatment of resistant hypertension are also discussed in this article.

Author Biographies

Salwa Salsabila Nasution, Universitas Lampung

 

 

Intanri Kurniati

 

 

Maya Ganda Ratna

 

 

M. Ricky Ramadhian

 

 

References

Tamsil Y, Moeis ES, Wantania F. Gambaran Anemia pada Subjek Penyakit Ginjal Kronik Stadium 4 dan 5 di Poliklinik Ginjal-Hipertensi RSUP Prof. Dr. R. D. Kandou. e-CliniC. 2019;8(1):60–6.

Yuniarti W. Anemia pada Pasien Gagal Ginjal Kronik Anemia in Chronic Kidney Disease Patients. J Heal Sci ; Gorontalo J Heal Sci Community. 2021;5(2):341–7.

Rampengan SH. Hipertensi Resisten Resistant Hypertension. J Kedokt Yars. 2015;23(2):114–27.

Ayunina Rizky Ferdina. Anemia pada Penyakit Ginjal Kronik. Mengen Anemia Patofisiologi, Klasifikasi, dan Diagnosis. 2023;6(2):31–8.

Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, et al. Anemia of Chronic Kidney Disease—A Narrative Review of Its Pathophysiology, Diagnosis, and Management. Biomedicines. 2024;12(6):1–23.

Fishbane S, Coyne DW. How I treat renal anemia. Blood. 2020;136(7):783-789.;

Sanjaya AAGB, Santhi DGDD, Lestari AAW. Gambaran Anemia Pada Pasien Penyakit Ginjal Kronik Di RSUP Sanglah Pada Tahun 2016. J Med Udayana. 2019;8(6):1–6.

Pernefri. Konsensus manajemen

anemia pada penyakit ginjal kronik. perhimpunan nefrologi indonesia. 2011. 7–14 p.

Salwani D, Syukri M, Abdullah A. Anemia pada Penyakit Ginjal Kronis. J Kedokt Nanggroe Med. 2023;6(2):31–8.

Usmani EY, Tri Kusuma Dewi R, Nurhayatun E. Perbandingan Kejadian Anemia Pada Pasien Penyakit Ginjal Kronis dengan Hipertensi Terkontrol dan Tidak Terkontrol. Plex Med J. 2022;1(2):60–7.

Rumjon A. Anemia and Chronic Kidney Disease. Med (United Kingdom). 2023;51(3):196–200.

Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72(3):537–48.

Teixeira RS, Terse-Ramos R, Ferreira TA, Machado VR, Perdiz MI, Lyra IM, et al. Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia. PLoS One. 2017;12(9):1–14.

Prenggono MD. Eritropoetin dan Penggunaan Eritropoetin pada Pasien Kanker dengan Anemia. Cdk. 2015;42(1):20–8.

Sun P, Kumar N, Tin A, Zhao J, Brown M. Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease. AHA/ASA Journals. 2021;78(5).

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. Vol. 72, Hypertension. 2018. 53–90 p.

Georgianos PI, Agarwal R. Hypertension in chronic kidney disease - Treatment standard 2023. Nephrol Dial Transplant [Internet]. 2023;38(12):2694–703. Available from: https://doi.org/10.1093/ndt/gfad118

Published

2025-02-17

How to Cite

Nasution, S. S., Kurniati, I., Ratna, M. G., & Ramadhian, M. R. (2025). The Role of Anemia as a Risk Factor for Resistant Hypertension in Chronic Kidney Disease. Medical Profession Journal of Lampung, 14(10), 1862-1867. https://doi.org/10.53089/medula.v14i10.1354

Issue

Section

Artikel

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 > >>